drugset / Trial / NCT03291067

MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women

NCT03291067

Phase 2 Completed 375 enrolled Tanabe Pharma America, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of MT-8554 for treatment of vasomotor symptoms (VMS) associated with menopause.

Timeline

Start
2017-10-09
Primary completion
2018-10-19
Completion
2018-11-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Elismetrep Small molecule 1 mg Oral
Subject Elismetrep Small molecule 5 mg Oral
Subject Elismetrep Small molecule 10 mg Oral

Indications